Novel reduced dose pharmaceutical compositions of fexofenadine and pseudoephedrine
AssigneeLupin Limited
InventorsUbaidulla Udhumansha, Shirishkumar Kulkarni
Life of this patent
Estimating the term…
Abstract
A novel reduced dose pharmaceutical composition comprising combination of fexofenadine or salts thereof; and pseudoephedrine or salts thereof in therapeutically effective amount, for the treatment of allergic rhinitis and associated symptoms in pediatric population.
Claims17
A novel reduced dose pharmaceutical composition comprising combination of fexofenadine or salts thereof;
- and pseudoephedrine or salts thereof in therapeutically effective amount, for the treatment of allergic rhinitis and associated symptoms in pediatric population.
A novel reduced dose pharmaceutical composition comprises combination of fexofenadine or salts thereof;
- and pseudoephedrine or salts thereof in therapeutically effective amount, wherein therapeutically effective amount of fexofenadine or salts thereof is in the range of 10 mg to 60 mg and psuedoephedrine or salts thereof in the range of 20 mg to 120 mg for pediatric population.
A novel reduced dose pharmaceutical composition comprises combination of fexofenadine or salts thereof;
- and pseudoephedrine or salts thereof in therapeutically effective amount, wherein the therapeutically effective amount of fexofenadine or salts thereof is 30 mg and psuedoephedrine or salts thereof is 60 mg for pediatric population.
A novel reduced dose pharmaceutical composition comprising a kit;
- wherein the kit comprises:
- (a) an oral solid dosage forms comprising a therapeutic amount of fexofenadine or salts thereof (b) an oral solid dosage forms comprising a therapeutic amount of pseudoephedrine or salts thereof wherein fexofenadine and pseudoephedrine are packed on separate sheets or by packaging fexofenadine on one side and a pseudoephedrine on the other side of one and the same sheet or by packaging the doses of both preparations for one course of treatment.
A novel reduced dose pharmaceutical composition comprises combination of fexofenadine or salts thereof;
- and pseudoephedrine or salts thereof in therapeutically effective amount, wherein the therapeutically effective amount of fexofenadine or salts thereof is 30 mg and psuedoephedrine or salts thereof is 60 mg for pediatric population is a liquid oral dosage form.
A novel reduced dose pharmaceutical composition comprising combination of fexofenadine or salts thereof;
- and pseudoephedrine or salts thereof in therapeutically effective amount, wherein said composition exhibits in vitro release of the fexofenadine in 0.1 N HCl of not less than about 80% after 2 hours, and/or in vitro release of pseudoephedrine or salts thereof in 0.001 N HCl of not less than about 80% after 22 hours.
Dependencies are inferred from the claim text.